-transparent.png){kind=logo}
The clinical course, serological changes and the development of the specific cell-mediated immune response to Epstein-Barr-Virus (EBV), measured in terms of leukocyte migration inhibition, were followed in 40 children suffering from an EBV infection. The patients were followed for between six and 24 months. Although the majority of the children were under six years of age, they presented a typical clinical course; heterophil antibodies could only be demonstrated in 60% of the cases. Anti-VAC-IgM and IgG antibodies were found in all patients during the acute phase, but no anti-EBNA could be demonstrated. In children under three years of age, no antibodies against the D component of the early antigen were found; this antibody was found in 50% of the adolescents. An antibody against the R component of the early antigen could be demonstrated in 73% of the children five to six months after the onset of the disease. Specific leukocyte migration inhibition was present only during convalescence or later. A relationship between the appearance of anti-EBNA and the development of specific leukocyte migration inhibition has been established.
L Timár, and
J Budai, and
M Koller
August 1981,
American journal of diseases of children (1960),
L Timár, and
J Budai, and
M Koller
March 1974,
Pediatrics,
L Timár, and
J Budai, and
M Koller
February 2001,
Clinical otolaryngology and allied sciences,
L Timár, and
J Budai, and
M Koller
March 1971,
Hippokrates,
L Timár, and
J Budai, and
M Koller
October 2004,
American family physician,
L Timár, and
J Budai, and
M Koller
September 1974,
Human pathology,
L Timár, and
J Budai, and
M Koller
May 1980,
Orvosi hetilap,
L Timár, and
J Budai, and
M Koller
November 2004,
Expert reviews in molecular medicine,
L Timár, and
J Budai, and
M Koller
February 1973,
The New England journal of medicine,
L Timár, and
J Budai, and
M Koller
February 1986,
The Quarterly journal of medicine,
